Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 2008

View Archived Issues

Once-yearly Aclasta recommended for approval in E.U. for male osteoporosis

CombinatoRx presents an update on the company's activities

Recent patents disclose novel antiinflammatory agents

Novel treatment options for autoimmune diseases reported by AstraZeneca

Novel treatments for hepatitis C virus infection disclosed in recent patents

Raltegravir clinically effective in a triple-class drug resistance HIV-1 infection

Aeras to fund phase IIb clinical trials of AERAS-485/MVA-85A TB vaccine

First-in-human results with [11C]-GSK-215083 radioligand in imaging brain 5-HT6 receptor

[11C]-(+)-RX-821024, a promising novel tracer for imaging alpha2-adrenoceptors

Novel marker [18F]-AH-110690 tested in humans for the detection of early-stage Alzheimer's disease

Alexza initiates second phase III clinical trial of Staccato for acute agitation in schizophrenia

First-in-human results of Alzheimer's disease vaccine CAD-106

GSK and HSCI sign collaborative agreement in stem cell science

MacroChem reports phase II data for EcoNail in onychomycosis

Nabi presents positive interim results of NicVAX immunogenicity study

NicOx reports top-line results from naproxcinod 52-week 301 safety extension

Sound Pharmaceuticals files IND with FDA for SPI-3005 for ototoxicity

NuPathe raises USD 30 million in series B equity financing

FDA grants Ortho-McNeil pediatric exclusivity for Topamax

BioCryst's phase II peramivir study meets primary endpoint in influenza

Exforge shown to effectively control blood pressure

Innocoll doses first patient in third U.S. phase II CollaRx bupivacaine surgical implant trial

Nventa reports final data from HspE7 phase I cervical dysplasia trial

OP-145 found effective in phase II ear infection study

Sucampo initiates phase II cobiprostone trial in portal hypertension

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...